Dr. Brose’s [Damon Runyon-Siemens Clinical Investigator] laboratory focuses on the genomic characterization of cancers of the head and neck, thyroid and lung.  She is active in the area novel drug target discovery.  Dr. Brose is a pioneer in the treatment of advanced thyroid cancer and is currently studying the effectiveness of sorafenib in metastatic thyroid cancer patients.   Dr. Brose’s research interests include the use of genetic testing in diagnosis, prevention, prognosis, and treatment of cancer, including tobacco-related cancers, head and neck cancers, lung cancers, esophageal cancers, and thyroid cancers.

---

Project Title: "The emerging clinical role of genetics in the treatment and diagnosis of thyroid cancer"

Institution: University of Pennsylvania

Sponsor(s) / Mentor(s): Peter J. O'Dwyer, MD & Susan J. Mandel, MD, MPH

Cancer Type: Thyroid

Research Area: Genomics